Kronos Bio Overview
Kronos Bio (KRON) has a ROE of -80.8%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-80.80%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Kronos Bio (KRON) currently reports a ROE of -80.8%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Kronos Bio's ROE history and peer comparisons.
Kronos Bio's ROE of -80.8% is lower than the Healthcare sector average of 29.39%. That is roughly 374.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Kronos Bio's current -80.8% should be judged against Healthcare norms (sector average: 29.39%) and against KRON's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -80.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Kronos Bio, and consider following KRON for alerts when major investors trade the stock.
Kronos Bio is classified in the Healthcare sector. On ROE, it currently shows -80.8% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRON with unrelated industries.
